Rakan El-Mayta

Rakan El-Mayta

Auto-generated profile, based on publicly available information

Rakan El-Mayta

Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
NGNingqiang Gong
Ningqiang Gong
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
RERakan El-Mayta
Rakan El-Mayta
LXLulu Xue
Lulu Xue
DWDrew Weissman
Drew Weissman
MMMichael Mitchell
Michael Mitchell

9 August 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SSSarah J. Shepherd
Sarah J. Shepherd
XHXuexiang Han
Xuexiang Han
AMAlvin J. Mukalel
Alvin J. Mukalel
RERakan El-Mayta
Rakan El-Mayta
ATAjay S. Thatte
Ajay S. Thatte
MMMichael Mitchell
Michael Mitchell
Lipid nanoparticles (LNPs) are a potent delivery technology that have made it possible for the recent clinical breakthroughs in mRNA therapeutics and vaccines. A key challenge to the broader implementation of mRNA therapeutics and vaccines is the development of technology to produce precisely defined LNP formulations, with throughput that can scale from discovery to commercial manufacturing and meet the stringent manufacturing standards of the pharmaceutical industry. To address these challenges, we have developed a microfluidic chip that incorporates 1×, 10×, or 256× LNP-generating units that achieve scalable production rates of up to 17 L/h of precisely defined LNPs. Using these chips, we demonstrate that LNP physical properties and potency in vivo are unchanged as throughput is scaled. Our chips are fabricated out of silicon and glass substrates, which have excellent solvent compatibility, compatibility with pharmaceutical manufacturing, and can be fully reset and reused. SARS-CoV-2 mRNA-LNP vaccines formulated by our chips triggered potent antibody responses in a preclinical study. These results demonstrate the feasibility of directly translating microfluidic-generated LNPs to the scale necessary for commercial production.

29 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
LXLulu Xue
Lulu Xue
AHAlex G. Hamilton
Alex G. Hamilton
GZGan Zhao
Gan Zhao
ZXZebin Xiao
Zebin Xiao
RERakan El-Mayta
Rakan El-Mayta
MMMichael Mitchell
Michael Mitchell
Lipid nanoparticles for delivering mRNA therapeutics hold immense promise for the treatment of a wide range of lung-associated diseases. However, the lack of effective methodologies capable of identifying the pulmonary delivery profile of chemically distinct lipid libraries poses a significant obstacle to the advancement of mRNA therapeutics. Here we report the implementation of a barcoded high-throughput screening system as a means to identify the lung-targeting efficacy of cationic, degradable lipid-like materials. We combinatorially synthesize 180 cationic, degradable lipids which are initially screened in vitro. We then use barcoding technology to quantify how the selected 96 distinct lipid nanoparticles deliver DNA barcodes in vivo. The top-performing nanoparticle formulation delivering Cas9-based genetic editors exhibits therapeutic potential for antiangiogenic cancer therapy within a lung tumor model in female mice. These data demonstrate that employing high-throughput barcoding technology as a screening tool for identifying nanoparticles with lung tropism holds potential for the development of next-generation extrahepatic delivery platforms.

1 October 2024 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
LXLulu Xue
Lulu Xue
GZGan Zhao
Gan Zhao
NGNingqiang Gong
Ningqiang Gong
XHXuexiang Han
Xuexiang Han
SSSarah J. Shepherd
Sarah J. Shepherd
MMMichael Mitchell
Michael Mitchell

9 July 2024 in Nature Chemistry
Verified
Journal Article
Closed access
PDF file
XHXuexiang Han
Xuexiang Han
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
NGNingqiang Gong
Ningqiang Gong
LXLulu Xue
Lulu Xue
MGMajed Ghattas
Majed Ghattas
MMMichael Mitchell
Michael Mitchell

26 February 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
XHXuexiang Han
Xuexiang Han
JXJunchao Xu
Junchao Xu
YXYing Xu
Ying Xu
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
LXLulu Xue
Lulu Xue
MMMichael Mitchell
Michael Mitchell
The ionizable lipidoid is a key component of lipid nanoparticles (LNPs). Degradable lipidoids containing extended alkyl branches have received tremendous attention, yet their optimization and investigation are underappreciated. Here, we devise an in situ construction method for the combinatorial synthesis of degradable branched (DB) lipidoids. We find that appending branch tails to inefficacious lipidoids via degradable linkers boosts mRNA delivery efficiency up to three orders of magnitude. Combinatorial screening and systematic investigation of two libraries of DB-lipidoids reveal important structural criteria that govern their in vivo potency. The lead DB-LNP demonstrates robust delivery of mRNA therapeutics and gene editors into the liver. In a diet-induced obese mouse model, we show that repeated administration of DB-LNP encapsulating mRNA encoding human fibroblast growth factor 21 alleviates obesity and fatty liver. Together, we offer a construction strategy for high-throughput and cost-efficient synthesis of DB-lipidoids. This study provides insights into branched lipidoids for efficient mRNA delivery.